C5AR1 and COVID-19: Encouraging preliminary data have been reported for severely ill COVID‐19 subjects, who were either treated with a C3 antagonist (Mastaglio et al., 2020) and C5‐ or C5a‐blocking antibodies (Diurno et al., 2020; Gao et al., 2020).